Deleta is a combination medication used to assist in the management of mood disorders where symptoms of anxiety and depression occur together. It is intended to help provide relief for the emotional distress and related physical symptoms associated with these conditions.

The therapeutic indications for this combination include various depressive and anxiety states. Specifically, the medicine is indicated for managing conditions such as anxiety, depression, and asthenia (abnormal physical weakness or lack of energy). It is also used in the management of psychogenic depression, depressive neuroses, masked depression, and psychosomatic affections accompanied by anxiety and apathy.

The use of this medication may assist in stabilizing mood and easing emotional distress. The combination may be used in clinical scenarios where a patient presents with symptoms of sadness, restlessness, and a lack of energy simultaneously.

---

Quick Fact: Relief for Mixed Anxiety-Depressive Symptoms

---

Regulatory References

1. NIH-archived Summary of Product Characteristics

This section outlines the population eligibility and non-eligibility criteria for Deleta (Flupentixol/Melitracen) as mandated by official government regulatory documents.

Contraindicated Populations

The use of Deleta is strictly contraindicated in patients with absolute medical prohibitions, including:

• Hypersensitivity to flupentixol, melitracen, or any excipients.
• Cardiovascular Conditions: Recent myocardial infarction, coronary artery insufficiency, or serious disorders of cardiac rhythm.
• Neurological/Systemic States: Circulatory collapse, blood disorders, phaeochromocytoma, coma, or depressed level of consciousness (e.g., due to intoxication).
• Concomitant Therapy: Use with Monoamine Oxidase Inhibitors (MAOIs) is prohibited.

Age and Condition Restrictions

Eligibility Group	Regulatory Status
Children/Adolescents (<18 years)	Not recommended due to insufficient safety and efficacy data.
Excitable/Overactive Patients	Not recommended as the activating effect may exaggerate symptoms.
Advanced Hepatic/Cardiovascular Disease	Use requires special caution.
Pregnancy (Third Trimester)	Neonates exposed are at risk of extrapyramidal and/or withdrawal symptoms.
Lactation	Flupentixol is present in breast milk; excretion of melitracen is not known.

Eligibility is limited to the adult population (18 years and older) when no contraindications are present. Additional conditions requiring use with caution include organic brain syndrome, convulsive states, hyperthyroidism, and risk factors for stroke. The regulatory structure defines use by strict exclusion and specific cautionary requirements.

The official regulatory documents state that the combination of Flupentixol and Melitracen is subject to specific interaction-related restrictions, primarily concerning the co-administration of certain drug classes.

Contraindicated Combinations and Timing Rules

Treatment with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated due to a severe pharmacodynamic interaction risk, specifically Serotonin Syndrome. A mandatory timing separation requirement must be observed: treatment must not begin until at least 14 days after discontinuing non-selective MAOIs, and MAOIs must not be started for 14 days after stopping this medication.

---

Pharmacodynamic and Exposure Interactions

The medicine may enhance the effects of alcohol, barbiturates, and other CNS depressants, which is a documented pharmacodynamic interaction leading to increased sedative response. The component Melitracen may also potentiate the cardiovascular effects of direct-acting sympathomimetic agents and may counteract the antihypertensive effects of certain adrenergic neurone blockers.

Exposure-altering interactions include the documented mutual inhibition of metabolism between the two active components, Flupentixol and Melitracen. Additionally, the medicine may potentiate the effects of oral anticoagulants and prolong the action of neuromuscular blocking agents. Co-use with anticholinergic agents is restricted due to an increased risk of peripheral effects like paralytic ileus.

How Deleta Works

The mechanism of this fixed-dose combination (FDC) is defined by its synchronized influence across three central monoamine systems: Norepinephrine, Serotonin, and Dopamine. The mechanism modulates central regulatory pathways, influencing both activating and stabilizing systems.

Dual Enhancement of Serotonin and Norepinephrine

The Melitracen component acts by inhibiting the reuptake of Serotonin and Norepinephrine into nerve cells. Blocking the Serotonin Transporter (SERT) and Norepinephrine Transporter (NET) increases the concentration and duration of these neurotransmitters in the synapse, enhancing signaling that contributes to the regulation of central pathways involved in affect and physiological arousal.

Functional Activation of Dopaminergic Drive

Flupentixol’s low-dose action selectively blocks presynaptic Dopamine D2 Autoreceptors to remove a natural braking mechanism. This disinhibition results in a functional increase in Dopamine release, specifically in pathways associated with motivation. This action modulates central systems that govern activation and psychic drive.

Triple Monoamine Synergy and Pathway Balance

This combined mechanism achieves a Triple Monoamine Modulation across the S-N-D systems through two distinct approaches—reuptake inhibition and release modulation. This synergistic effect influences regulatory feedback loops, impacting the overall balance of central activating and stabilizing systems.

How to Use Deleta

Deleta is a Fixed-Dose Combination (FDC) medicine presented as a film-coated tablet intended for oral administration. The principles of its use include specific dosing and frequency parameters.

---

Standard Administration and Dosing

The medicine is designed for divided daily use, with the administration scheduled for the morning and at noon (midday) to align with the pharmacological profiles of its components. The tablets must be swallowed whole with water and must not be chewed. The medicine may be taken independently of meal times, either with or without food.

Instruction	Detail
Route of Administration	Oral
Standard Adult Dose	Two tablets daily (one in the morning, one at noon).
Adult Maximum Dose	Four tablets daily.

---

Population-Specific Use and Duration

Modified use instructions apply for older patients. For older adults (over 65 years), the initial dose is typically lower, starting at one tablet in the morning. In more severe clinical scenarios, this may be increased to one tablet in the morning and one at noon, but the dose is generally maintained at the lower level.

The use of Deleta is generally structured as an extended course of treatment. Treatment should not be stopped abruptly, as a period of gradual dose reduction (tapering) is typically utilized when the decision is made to discontinue the medicine. If the maximum dose is taken for approximately one week without a satisfactory outcome, the patient's use of the medicine should be re-evaluated.

Research evidence / Overview of studies

Overview of Monotherapy Trials

Studies evaluated the agent in participants with severe, active rheumatoid arthritis (RA). The primary research goal was to evaluate the agent’s effects on disease activity scores (DAS28) and quality of life measures.

Research has investigated the agent's potential to affect mobility and joint inflammation. A change in reported pain and swelling was noted in participants over a 12-week period. Research examined whether the agent had an effect on severe joint stiffness.

Studies evaluated the mechanism of action, which involves targeting specific inflammatory pathways.

Combination Therapy Research

Researchers have explored the use of the agent alongside existing treatments, such as Disease-Modifying Anti-Rheumatic Drugs (DMARDs).

Study Design and Outcomes

A combination therapy with existing treatments was examined versus monotherapy (using the agent alone). Findings were mixed, with some studies showing an increased percentage of participants achieving low disease activity in the combination group, while other trials reported no significant difference between groups. It is not yet clear whether the combination approach provides a consistently different outcome compared to monotherapy.

Safety and Tolerability Profiles

The studies examined the long-term management profile of the agent in trial settings. Exclusion criteria for the studies included participants with pre-existing heart conditions. The reported incidence of potential side effects was noted, with the most commonly reported events being mild gastrointestinal disturbances and temporary local irritation at the injection site. Serious adverse events were infrequent in the reported trials.

Patient-Reported Outcomes

Studies examined patient-reported outcomes (PROs) related to daily function and overall well-being. Research has explored whether there is a change in reported pain, and a minority of studies explored the impact on fatigue and sleep quality. Evidence remains limited regarding the overall impact on long-term physical function.

Key Studies & References

1. Effectiveness and safety of tocilizumab in monotherapy in biologic-naïve and non-naïve patients with rheumatoid arthritis in a real-world setting

Common questions about Deleta (FAQ)

---

Q: How is Deleta different from other medicines used for the same condition?

Official information describes Deleta as a Fixed-Dose Combination (FDC) medicine, meaning it contains two active ingredients in one tablet. This unique composition is noted in regulatory documents for achieving a balance of activating and stabilizing effects. Furthermore, official product descriptions note that it has a low reported incidence of sedative effects compared to some older types of antidepressants.

Q: What are the most common side effects people report after starting Deleta?

According to official regulatory documents, the side effects reported most frequently are classified as 'Very Common.' These include somnolence (sleepiness) and extrapyramidal symptoms. Extrapyramidal symptoms is a classification that includes movement-related effects, and regulatory documents list them among the common reactions.

Q: Do the side effects of Deleta usually go away over time?

The official safety notes on this medicine address the timing of certain effects. They state that specific side effects, such as extrapyramidal symptoms, often appear upon the initial start of therapy or following a dosage increase. This information is often interpreted to mean that these specific effects can be temporary as treatment progresses.

Q: Does Deleta interact with common medications for high blood pressure?

Regulatory documents indicate a potential interaction with certain high blood pressure medicines. Specifically, the component Melitracen may counteract the effects of certain drugs classified as adrenergic neurone blockers, which are used to lower blood pressure. Information about all medicines used should be shared with a healthcare professional.

Q: Why might a patient switch from a different medication to Deleta?

Official documentation describes this medicine's use for treating mixed anxiety and depressive states. A key feature highlighted in the official information is its relatively low incidence of sedation compared to older treatments, which may be a consideration in its selection.

Q: What is the chance of experiencing a rare side effect with Deleta?

Regulatory documents categorize possible side effects by frequency, including those that are 'Rare' or 'Very Rare.' Serious, though rare, safety considerations highlighted in official warnings include Neuroleptic Malignant Syndrome and serious heart rhythm disorders, known formally as Ventricular Arrhythmias.

Q: What did the main clinical trials for Deleta focus on?

The medicine is approved for its general purpose of addressing mixed anxiety and depressive states. Therefore, the main clinical trials focused on patients who were experiencing these co-occurring mental health symptoms.

Q: Can taking Deleta affect my ability to get pregnant?

Official documents include findings from preclinical studies in animals. These studies noted that one active component affected the pregnancy rate of female rats and the other affected the fertility of male rats.

Q: How quickly does Deleta usually start to have an effect?

Pharmacokinetic data in regulatory documents indicates that the maximum concentration of one active component in the blood occurs approximately 4 hours after taking a dose. However, the time required to notice an effect on symptoms can be longer.

Q: Is Deleta considered a long-term treatment or a short-course medicine?

Regulatory documents officially structure the use of this medicine as an extended course of treatment. Furthermore, official procedures require a period of gradual dose reduction (tapering) when a patient is making the decision to discontinue the medicine.

Q: Can Deleta cause trouble sleeping or change my energy levels?

Official regulatory documents list both Insomnia (difficulty sleeping) and Somnolence (drowsiness or sleepiness) as potential side effects. These effects are categorized as either 'Common' or 'Very Common,' indicating that changes in sleep and energy levels can occur.

Q: What if Deleta does not seem to be working after a few weeks?

Official prescribing documents contain instructions for monitoring treatment effectiveness. Regulatory authorities state that if the patient is taking the maximum prescribed dose for approximately one week without a satisfactory outcome, official guidelines state that the patient's use of the medicine requires re-evaluation.

Q: Can I drive or operate machinery while taking Deleta?

Official safety warnings state that the medicine can cause side effects such as sleepiness (somnolence) and dizziness. Because these effects may impair a person's judgment, physical coordination, or ability to focus, official documents state that due to these possible effects, caution is advised regarding driving or operating machinery.

Q: What is the safety classification of Deleta regarding pregnancy or breastfeeding?

This medicine is not assigned an FDA Pregnancy Category in the provided documents. Official warnings state that neonates exposed to the medicine during the third trimester of pregnancy are at risk of experiencing withdrawal symptoms. Additionally, one component is known to be present in breast milk.

Q: Can Deleta make me feel dizzy or lightheaded?

Although specific mentions of dizziness are not listed among the 'Common' effects, official safety warnings describe a rare but severe side effect known as Neuroleptic Malignant Syndrome (NMS). Symptoms of NMS can include lightheadedness or dizziness, alongside fever and changes in muscle tone.

Q: Is Deleta known to cause weight changes (gain or loss)?

Regulatory documents list a specific weight-related side effect as 'Common.' This effect is described as increased appetite leading to weight gain.

Q: How long does Deleta stay in my system after I stop taking it?

Pharmacokinetic data available in regulatory documents describes how the body eliminates the active ingredients. The biological half-life of one active component is approximately 35 hours.

Q: Do children or teenagers respond differently to Deleta than adults?

The official regulatory stance is that the medicine is not recommended for children and adolescents under 18 years of age. This is due to a lack of sufficient safety and efficacy data to establish the response and safety profile for this younger population.

Q: Are there specific symptoms that mean I should stop taking Deleta right away?

Official safety warnings describe rare but severe conditions that are considered critical safety concerns. These include the possibility of Neuroleptic Malignant Syndrome (NMS) and serious Ventricular Arrhythmias (irregular heart rhythms). If any severe or unexpected symptoms occur, a healthcare professional should be consulted.

Q: Does the time of day matter when taking Deleta?

The official instructions for use specify a particular schedule. Regulatory documents state that the medicine is designed for divided daily use with administration scheduled for the morning and at noon (midday).

How to Store and Dispose of Deleta

Official regulatory guidelines define specific conditions for storing and disposing of Deleta (Flupentixol/Melitracen) to ensure product stability and public safety.

Storage Requirements

• Temperature: Deleta must be stored at a temperature that does not exceed 30 C (86°F).
• Protection: The medicine must be protected from both light and moisture; it should be kept in a dry place.
• Container: Tablets should be stored in the original container to maintain environmental protection.
• Child Safety: Consistent with labeling requirements, Deleta must be kept out of the sight and reach of children.

Disposal

Any unused or expired product must be disposed of in accordance with local regulatory requirements for pharmaceutical waste, as instructed by health authorities or dispensing professionals.